Leber congenital amaurosis: Can CRISPR cure genetic blindness?
Looks at a clinical trial that uses CRISPR technology to cure a type of genetic blindness called Leber congenital amaurosis (LCA).
A clinical trial in the United States is looking to cure a type of genetic blindness called Leber congenital amaurosis (LCA) with the use of CRISPR technology.
More information on this clinical trial:
[Please complete our feedback form]
Demystifying Medicine, Education, Eye health, Genetics
Related News
News Listing
Daily News ➚
5 McMaster students named McCall MacBain International Fellows
Collaborations & Partnerships, Education, Funding
6 days ago
Here’s what you need to know about stroke in women
Education, School of Rehab Sciences
June 27, 2024
Department of Pediatrics ➚
Behind the White Coat: A conversation with pediatric neurology resident Hannah Snyder
Education
June 25, 2024